AssAssertio Holdings Inc (ASRT)

[dcaf7]

On Hanmi. Brokerages raise stock price targets for Korean traditional pharma citing licensing deals, export gains.
Daishin Securities set the target prices for Hanmi Pharm and Yuhan Corp. from the current 315,500 won and 63,300 won to 420,000 won and 92,000 won, respectively. Hanmi has strengths in the continued steady profit growth through the sales of key products like Rosuzet, Amozaltan family, and Rolvedon.

[dcaf7]

Hanmi is ready to conduct a Phase 4 study "Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)". Title is misleading since they are using Eflapegrastim (Rolvedon), not Pegfilgrastim (Neulasta). You can see it in official title, "Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy". Here is a rationale for this study, "It is known that patients who experience neutropenia after the first round of chemotherapy are more likely to experience it again in subsequent rounds. The investigators aimed to see whether changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy for patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round can reduce the incidence of neutropenia".
https://classic.clinicaltrials.gov/ct2/show/NCT05949333?term=eflapegrastim&draw=2&rank=2

[Johnny R]

very disappointing earnings release . . . . and the insiders all sold their stock to cover taxes on their options . . . . sure, whatever you say

[Johnny R]

wow that has been kept quiet. I presume it will be discussed in the quarterly earnings call

[dcaf7]

Hanmi posted 3dQ results. In their presentation you can find, "pan HER - preparing for global phase 3 trial" with Assertio as a partner.
http://www.hanmi.co.kr/upfile/ces/information/INFORMATION_PRESENTATIONS/90166507/127540fe-3519-4cb1-95bb-0ce29cb172ee.pdf

[dcaf7]

From VA Formulary Advisor.
Projected Place in Therapy/Conclusions
• In 2 phase III clinical trials in patients with early breast cancer receiving myelosuppressive chemotherapy for 4
cycles in the adjuvant setting, eflapegrastim was non-inferior to pegfilgrastim in reducing the duration of severe
neutropenia during cycle 1 (primary endpoint) and during cycles 2-4 (secondary endpoint). Pooled rates of febrile
neutropenia for this chemotherapy combination without G-CSF prophylaxis are 29.1%.
• Safety during the clinical trial (adverse reactions in ≥20%) was similar between eflapegrastim and pegfilgrastim
despite the fact that eflapegrastim provides a lower dose of G-CSF compared to pegfilgrastim. The package
labeling for both products contains the same contraindication and Warnings and Precautions.
• There is no clear place in therapy for eflapegrastim instead of pegfilgrastim.
https://www.va.gov/formularyadvisor/DOC/466

[dcaf7]

Ha ha. Good job. Posted by Defense World Staff on Aug 25th, 2023. Equities research analysts at StockNews.com began coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Free Report) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

[dcaf7]

Rolvedon vs biosimilars cost.
The final 2 articles highlighted in this issue of the Medical Letter address the question of cost. The first notes the recent approval of the new bone marrow stimulatory agent eflapegrastim-xnst (Rolvedon) for the prevention of chemotherapy-induced febrile neutropenia. The agent was FDA approved based on the results of 2 randomized trials in which it demonstrated noninferiority in one trial and possible superiority in the other trial vs pegfilgrastim (Neulasta).

Although there should always be interest in discovering novel, increasingly effective, less toxic approaches to supportive care measures in cancer management, the question here is the value of such agents vs less expensive biosimilar agents employed for this purpose. One dose of eflapegrastim is said to cost $4500 compared with pegfilgrastim biosimilar costing approximately $2500. This sum is not insignificant considering the common use of bone marrow stimulatory agents by oncology practices and health care systems, as well as the financial impact on third-party payers or as increasingly mandated insurance co-pay for individual patients.
https://www.onclive.com/view/unresolved-issues-in-antineoplastic-drug-therapy-is-it-finally-time-to-address-

[rado]

A few quotes from the call from Dan Peisert

"We believe we can certainly accelerate the path to profitability, and possibly accelerate the trajectory to a broader reach than what the in-person team has been able to do to date to drive awareness to physicians as well as to purchasing managers."

"... should enhance our access to the capital markets at a lower cost of capital than either company had on a standalone basis and accelerate our future M&A strategies so we can leverage both our platforms with complementary assets..."

"...but the synergies will come largely from the contracting and the access teams that will be a tremendous benefit to rest of the Assertio portfolio"

Dan Peisert also noted that this accelerate their plans and be highly accretive in 2024 and that this is a blockbuster product. There was some mention of 600+ clinics that Spectrum had access to whereas ASRT had access to 2000+ clinics. So the Spectrum product will get advertised more broadly than before, ASRT will probably get access to new clinics and relationships with their non-contact platform.

[rado]

The ASRT purchase conference call
https://events.q4inc.com/attendee/994427686/guest?t=1682444171300

[1hot toddy]

WOOOOOOOOOOW 2-10K BUYS, ONE 5K BUYS. SMART MONEY BUYING NOT SELLING $$$$$$$$$$

[saigai]

well now..seems like this is the ground floor..saw it a while back and forgot about it so i could have gotten in earlier but im happy.. this is a real equity building event they will leverage some very important assets to shoot the moon.. the best part is the cash position and cfp of many milions a year.. a cash cow..,,enjoy while we can

[saigai]

i dont want to see the 5 dollar space anymore i want 50 but not today because i am doubling up tomorrow.. this is the one that gets me back in the game just need to be patient

[1hot toddy]

221000 SHARE BUY ON THE CLOSE $$$$$$$$$$$$$$$$ OVER MIL $ BUY

[saigai]

shorts having a field day

[Alan Brown]

Going up ~

[crawford2012]

$Assertio Holdings Inc This is a very smart move by the company, here is why and what it does. In short, buy the friking dip.
These transactions?? reduce our overall debt by $30M, or 42.9%, while consuming only $10.5M in cash (and issue ~$7M shares). In addition, the transactions will ??save the company $2M in annual interest payments, reduce the potential dilution from the exchanged convertible notes by 4.6%, and will be accretive to our diluted EPS by $0.02 in 2023," CEO Dan Peisert commented.

??????????????????????????????

[saigai]

wish i had some powder to put here

[yankee2]

ASRT $3.00 Looking good so far

https://www.barchart.com/stocks/quotes/ASRT/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=ASRT&grid=1&height=500&studyheight=100


glta

[TrendTrade2016]

ASRT picking up speed now!!!

[TrendTrade2016]

ASRT ...rock star biotech!!!

[TrendTrade2016]

ASRT the trend is your friend

[TrendTrade2016]

ASRT wowza...trading to perfection!

[TrendTrade2016]

ASTR ready to go

[TrendTrade2016]

ASRT...one of the best and safest bio plays!!

[TrendTrade2016]

BIO season kicking in...ASRT shaping up!!

[wesley_]

$1.66 nice :)

[TheFinalCD]

https://ih.advfn.com/stock-market/NASDAQ/assertio-ASRT/stock-news/86470022/quarterly-report-10-q

[Jake L]

ASRT - WALLSTREETBETS WATCHLIST

[yankee2]

Good Morning ASRT $1.82 headed higher by the looks of things

https://www.barchart.com/stocks/quotes/ASRT/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=ASRT&grid=1&height=500&studyheight=100

glta

[ClayTrader]

* * $ASRT Video Chart 05-26-2021 * *

Link to Video - click here to watch the technical chart video

[Disquisition]

RELENTLESS DUMPING

[realfast95]

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split
May 17 2021 - 06:32AM
GlobeNewswire Inc.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has filed a Certificate of Amendment to its certificate of incorporation (the “Certificate of Amendment”) to implement a one-to-four reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on May 18, 2021, and the Company’s common stock will begin trading on a split-adjusted basis when the market opens on May 18, 2021.

[ed243383]

Now is the time to snag this while the entire market is down. The earnings speak for themselves. GL to all!!!

[ed243383]

This is a great entry point. Earnings looked great! Time to jump in while the price is below .50. IMO I think this will shoot right back up to close to $1 soon. GL to all!

[ClayTrader]

* * $ASRT Video Chart 05-07-2021 * *

Link to Video - click here to watch the technical chart video

[Eaglepointone]

Good player, in the process of transformation, has potential.
0,68$/share.

[irecruit]

That’s not always a bad thing. Gonna be a good day tomorrow for the few of us then!

[Technerdist]

Why is this board so dead?

[ClayTrader]

* * $ASRT Video Chart 02-10-2021 * *

Link to Video - click here to watch the technical chart video

[slow_feet]

Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering


LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced it has entered into a securities purchase agreement with certain institutional investors to purchase 35,000,000 shares of its common stock at a price of $0.98 per share, which is a premium to market based on applicable Nasdaq "minimum price" rules...

Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering

[ClayTrader]

* * $ASRT Video Chart 02-09-2021 * *

Link to Video - click here to watch the technical chart video

[wesley_]

$1.31 nice gains

[weedtrader420]

WOOHOOOOOOO

[ClayTrader]

* * $ASRT Video Chart 02-08-2021 * *

Link to Video - click here to watch the technical chart video

[weedtrader420]

yes

[wesley_]

$.94 nice

[Taking_Profits]

Ummmm Short Squeeze?
Short Interest is only 2% .
Technically 1.10 would be key resistance the 8 ema has crossed the 200.
It made nice moves when the 8 and 30 crossed the 50 on the daily chart.
So it has some potential for profit.
I don't think it will squeeze

[weedtrader420]

It's trading up now next week should be good short squeeze coming ASRT$ WOOHOOOOOOOOO

[JamieE]

And todays price is 62 cents /offering ??? Where do you come up with 3 dollars ?